Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 3/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7419737 | 0.93 | LPAR1 (0.46) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL28458040 | 0.87 | USP2 (0.48) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL7415858 | 0.87 | HSD17B10 (0.34) | — | |
| SCHEMBL7097325 | 0.87 | THRB (0.33) | — | |
| SCHEMBL8971436 | 0.85 | USP2 (0.48) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL10908954 | 0.83 | USP2 (0.52) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL9850818 | 0.83 | USP2 (0.52) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL6975117 | 0.83 | USP2 (0.52) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL703945 | 0.82 | LPAR1 (0.41) | LPAR1LPAR3LPAR2USP2HTT | |
| SCHEMBL11522848 | 0.81 | HTT (0.53) | LPAR1LPAR3LPAR2USP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105563-A1 | SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES | PFIZER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11850237-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-2445349-B1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES LC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3895706-A1 | THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS | Romark Laboratories, L.C. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10912768-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2021-02-09 | — | — | US | disclosed |
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES L.C. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10363243-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2019-07-30 | — | — | US | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | PHARMACIA CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-6545021-B1 | Including ether and ester derivatives as well as N-carbonyl derivatives | G.D. SEARLE & CO. | 2003-04-08 | — | — | US | disclosed |
| US-6515028-B1 | Used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| EP-1173161-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1165080-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001008672-A2 | GLUCAMINE COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000047198-A2 | USE OF SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912768-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | LPAR1 1272/4885LPAR3 1931/4885LPAR2 1972/4885 |
| US-20030195229-A1 | Glucamine salts for treating hepatitis virus infections | UGGT1, GYS2, MGAT3 | LPAR1 3684/4885LPAR3 4438/4885LPAR2 4524/4885 |
| US-20210177809-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | LPAR1 1272/4885LPAR3 1931/4885LPAR2 1972/4885 |
| US-20190307730-A1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | HIF1AN, HAVCR2, NEU1 | LPAR1 1272/4885LPAR3 1931/4885LPAR2 1972/4885 |
| US-11850237-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | LPAR1 1272/4885LPAR3 1931/4885LPAR2 1972/4885 |
| US-10363243-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | LPAR1 1272/4885LPAR3 1931/4885LPAR2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.